The Propel Mini Sinus Implant: A Breakthrough in Chronic Sinusitis Treatment with Nomisma’s PLGA
The Propel mini sinus implant has revolutionized the treatment of chronic sinusitis, providing a cutting-edge solution that combines effective drug delivery with advanced biodegradable polymer technology. This FDA-approved device, developed by Intersect ENT, utilizes mometasone furoate (370 micrograms) to deliver localized anti-inflammatory treatment over a month. At the heart of this innovation is PLGA (poly(lactic-co-glycolic acid)), a biopolymer known for its versatile and customizable properties.
PLGA in the Propel Mini Sinus Implant
Nomisma Healthcare, a leading manufacturer of biopolymers, supplies high-quality PLGA for medical applications like the Propel mini implant. The specific PLGA used in this device is meticulously engineered to ensure precise drug release, biocompatibility, and degradation characteristics. Here are the critical specifications of the polymer:
- Composition Ratio (LA:GA): The PLGA in the Propel mini implant uses a 50:50 ratio of lactic acid (LA) to glycolic acid (GA), optimized for controlled degradation and drug release.
- End-Termination: The polymer is acid-terminated, enhancing its degradation properties and ensuring compatibility with the drug delivery system.
- Molecular Weight (MW): The PLGA has a molecular weight of 12,000 Da, balancing mechanical strength with a predictable degradation profile.
- Intrinsic Viscosity (IV): The intrinsic viscosity of the polymer is aligned with its molecular weight and drug release performance, ensuring efficient functionality.
- Degradation Rate: The polymer degrades over 4-6 weeks, aligning perfectly with the therapeutic duration of mometasone furoate.
The Role of Nomisma’s PLGA
Nomisma’s PLGA stands out due to its exceptional purity, customizable properties, and proven efficacy in drug delivery systems. Our stringent quality control processes ensure consistent polymer characteristics, enabling innovative medical solutions like the Propel mini implant. By leveraging Nomisma’s expertise, Intersect ENT has been able to create a device that significantly improves patient outcomes in chronic sinusitis treatment.
Advantages of PLGA in Sinus Implants
- Localized Drug Delivery: PLGA enables controlled, localized delivery of mometasone furoate, reducing systemic side effects.
- Biocompatibility: PLGA is FDA-approved and demonstrates excellent compatibility with human tissues.
- Predictable Degradation: The polymer degrades into lactic acid and glycolic acid, which are naturally metabolized by the body.
- Customizability: Properties such as LA:GA ratio, molecular weight, and end-group modification can be tailored for specific medical needs.
Conclusion
The Propel mini sinus implant exemplifies the transformative potential of PLGA in medical devices. Nomisma Healthcare is proud to be at the forefront of this innovation, supplying the high-quality PLGA that powers such breakthroughs. By partnering with Nomisma, healthcare innovators can continue to push the boundaries of patient care with reliable, customizable biopolymers.
Reference: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0d775ef5-ee26-49f3-ac77-cee25cdd0c0a
For detailed studies and access to the referenced research papers, contact us directly. Let Nomisma’s expertise elevate your medical innovations.
Suprefact Depot, a sustained-release formulation containing Buserelin Acetate, has emerged as a breakthrough in the treatment of hormone-dependent conditions. As a luteinizing hormone-releasing hormone (LHRH) agonist, it is widely used to manage advanced prostate cancer and endometriosis. With convenient dosage options of 6.3 mg (every 2 months) and 9.45 mg (every 3 months), it ensures patient compliance and effective therapy.
PLGA 75:25: The Backbone of Controlled Release
The formulation of Suprefact Depot leverages PLGA 75:25, a biodegradable polymer composed of:
- Composition: 75% lactic acid and 25% glycolic acid.
- Molecular Weight: 20,000 – 50,000 g/mol.
- Inherent Viscosity (IV): 0.4 – 0.6 dL/g.
These properties allow precise control over the degradation rate and drug release profiles, making it ideal for sustained-release applications.
Applications of Suprefact Depot
Suprefact Depot’s unique formulation finds its primary applications in:
- Prostate Cancer Therapy:
- Suppresses testosterone levels to slow disease progression.
- Endometriosis Management:
- Reduces estrogen production, alleviating symptoms such as pain and inflammation.
- Fertility Treatments:
- Occasionally utilized in controlled ovarian stimulation protocols.
Why Choose Nomisma’s PLGA?
Nomisma Healthcare specializes in manufacturing high-quality PLGA tailored for pharmaceutical applications. The following features set Nomisma’s PLGA apart:
- High Purity & Biocompatibility: Ensures safety and efficacy in drug formulations.
- Customizable Properties: Offers tailored molecular weight and IV ranges to suit specific needs.
- Regulatory Compliance: Nomisma’s PLGA meets stringent standards for FDA-approved formulations.
Driving Innovation in Drug Delivery
Suprefact Depot exemplifies the transformative potential of Nomisma’s PLGA in advanced drug delivery systems. By ensuring controlled drug release and patient adherence, it highlights how innovative polymer technologies can redefine therapeutic outcomes.
References
- Klingmüller, D., & Schweikert, H. U. (1986). Buserelin acetate in the treatment of advanced prostate cancer. Cancer Treatment Reviews, 13(Suppl C), 47–52. DOI:10.1016/0305-7372(86)90008-7
- Jain, R. A. (2000). The manufacturing techniques of various drug-loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 21(23), 2475–90. DOI:10.1016/S0142-9612(00)00115-0
- Nomisma Healthcare. (2024). High-purity PLGA for advanced pharmaceutical applications.
Zilretta, an innovative formulation for managing osteoarthritis (OA) pain, has transformed the way extended-release corticosteroids are delivered to patients. This unique formulation uses PLGA (Poly(lactic-co-glycolic acid)) as a critical excipient, enabling a sustained release of the active ingredient for long-lasting pain relief.
What is Zilretta?
Zilretta is an extended-release injectable corticosteroid approved for the treatment of osteoarthritis-related knee pain. Unlike traditional corticosteroid injections, which provide short-term relief, Zilretta offers sustained pain management over weeks, enhancing patient outcomes and reducing the need for frequent interventions.
The key to Zilretta’s prolonged efficacy lies in its use of microsphere technology, enabled by PLGA 75:25. This biopolymer allows for controlled degradation and release of the corticosteroid into the affected joint, minimizing systemic side effects and maximizing local therapeutic impact.
Why PLGA 75:25 is Crucial for Zilretta
PLGA 75:25 is a copolymer consisting of 75% lactic acid and 25% glycolic acid. It is widely recognized for its biocompatibility, biodegradability, and ability to modulate drug release rates. The selection of PLGA 75:25 for Zilretta is driven by the following key properties:
- Controlled Degradation: The 75:25 ratio balances hydrophobicity and hydrophilicity, ensuring an optimal degradation timeline that aligns with the therapeutic needs of extended drug release.
- Microsphere Formation: PLGA 75:25 is ideal for creating uniform, stable microspheres that encapsulate the corticosteroid, enabling precise dosing and sustained release.
- Safety Profile: As a US FDA-approved polymer, PLGA 75:25 meets stringent safety standards, ensuring patient safety when used in injectable formulations like Zilretta.
Applications of PLGA in Drug Delivery
Beyond Zilretta, PLGA has established itself as a cornerstone in modern drug delivery systems, particularly for:
- Cancer Therapeutics: Delivering chemotherapy agents with minimal side effects.
- Vaccines: Enhancing the stability and release of antigens.
- Ophthalmic Treatments: Prolonging the effect of intraocular drugs.
Nomisma Healthcare’s Role in Advancing PLGA Applications
At Nomisma Healthcare, we specialize in the production of high-quality biopolymers, including PLGA, tailored for advanced pharmaceutical applications. Our PLGA 75:25 is manufactured to meet the rigorous demands of injectable drug delivery systems.
Why Choose Nomisma PLGA?
- Customizable Ratios: We offer precise control over lactide-to-glycolide ratios to suit specific drug release requirements.
- Pharmaceutical-Grade Quality: Our polymers comply with international regulatory standards, ensuring their safety and efficacy in therapeutic applications.
- Expert Support: With a dedicated team of scientists and technical experts, we collaborate with pharmaceutical companies to develop cutting-edge solutions.
Partner with Nomisma Healthcare
If you are developing innovative therapeutics like Zilretta or exploring other drug delivery systems, Nomisma Healthcare is your trusted partner for premium-grade PLGA. Our expertise and commitment to quality make us the ideal choice for your polymer needs.
Reach out to us at www.nomismahealthcare.com today to learn more about how our biopolymers can enhance your formulations and drive therapeutic innovation.
